Literature DB >> 14638407

Hepatitis C virus core protein transactivates the inducible nitric oxide synthase promoter via NF-kappaB activation.

Susana de Lucas1, Javier Bartolomé, María José Amaro, Vicente Carreño.   

Abstract

Intrahepatic levels of the inducible nitric oxide synthase (iNOS) are increased in chronic hepatitis C patients. As iNOS gene promoter contains Nuclear Factor (NF)-kappaB binding sites and hepatitis C virus (HCV) core protein activates NF-kappaB, the aim of this work was to study if HCV core protein transactivates iNOS promoter through NF-kappaB activation. iNOS mRNA and protein were determined by RT-PCR and western blot in HepG2 cells. The effect of HCV core protein on iNOS promoter was assayed by cotransfecting HepG2 cells with the core protein expression plasmid pHCV-Co and p1iNOS-CAT or p2iNOS-CAT plasmids. Formation of NF-kappaB-DNA complexes was determined by electrophoretic mobility shift assay. Transfection of HepG2 cells with pHCV-Co plasmid results in an increase in iNOS mRNA and protein levels. Cotransfection with pHCV-Co and p1iNOS-CAT or p2iNOS-CAT plasmids results in a transactivation of iNOS promoter, the presence of the proximal NF-kappaB binding site in the promoter being sufficient for the transactivation. Furthermore, the HCV core protein increases the formation of complexes between NF-kappaB and its binding sequence in the iNOS promoter. The expression of the NF-kappaB inhibitor IKB reverts the effect of the HCV core protein on the iNOS promoter. In conclusion, HCV core protein transactivates iNOS gene promoter through NF-kappaB activation.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14638407     DOI: 10.1016/j.antiviral.2003.08.006

Source DB:  PubMed          Journal:  Antiviral Res        ISSN: 0166-3542            Impact factor:   5.970


  7 in total

1.  Functional characterization of core genes from patients with acute hepatitis C virus infection.

Authors:  Xi Tang; Jessica Wagoner; Amina Negash; Michael Austin; John McLauchlan; Young S Hahn; Hugo R Rosen; Stephen J Polyak
Journal:  J Infect Dis       Date:  2010-03-15       Impact factor: 5.226

Review 2.  Viral hepatocarcinogenesis.

Authors:  W-L Tsai; R T Chung
Journal:  Oncogene       Date:  2010-03-15       Impact factor: 9.867

3.  Hepatitis C virus activates interleukin-1β via caspase-1-inflammasome complex.

Authors:  Dylan Burdette; Adam Haskett; Lance Presser; Steven McRae; Jawed Iqbal; Gulam Waris
Journal:  J Gen Virol       Date:  2011-10-12       Impact factor: 3.891

4.  Responses of nontransformed human hepatocytes to conditional expression of full-length hepatitis C virus open reading frame.

Authors:  Weiliang Tang; Catherine A Lázaro; Jean S Campbell; W Tony Parks; Michael G Katze; Nelson Fausto
Journal:  Am J Pathol       Date:  2007-11-08       Impact factor: 4.307

5.  Nitric oxide levels in chronic liver disease patients with and without oesophageal varices.

Authors:  Assem M El-Sherif; Mohamed A Abou-Shady; Ashraf M Al-Bahrawy; Reda M Bakr; Abdel-Moneim M Hosny
Journal:  Hepatol Int       Date:  2008-04-22       Impact factor: 6.047

6.  Role of free radicals in liver diseases.

Authors:  Pablo Muriel
Journal:  Hepatol Int       Date:  2009-11-26       Impact factor: 6.047

7.  Calcitriol Inhibits HCV Infection via Blockade of Activation of PPAR and Interference with Endoplasmic Reticulum-Associated Degradation.

Authors:  Yu-Min Lin; Hung-Yu Sun; Wen-Tai Chiu; Hui-Chen Su; Yu-Chieh Chien; Lee-Won Chong; Hung-Chuen Chang; Chyi-Huey Bai; Kung-Chia Young; Chiung-Wen Tsao
Journal:  Viruses       Date:  2018-01-30       Impact factor: 5.048

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.